Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421069 | 1.00 | CYP1A2 (0.55) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL546660 | 0.82 | CYP1A2 (0.40) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL17372391 | 0.79 | CYP1A2 (0.52) | CYP1A2HIF1ASMN1; SMN2CDK2CYP3A4 | |
| SCHEMBL29421093 | 0.79 | CYP1A2 (0.52) | CYP1A2HIF1ASMN1; SMN2CDK2CYP3A4 | |
| SCHEMBL31095854 | 0.75 | CYP1A2 (0.57) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL101602 | 0.75 | HTT (0.67) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL29359033 | 0.75 | HTT (0.67) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL9204579 | 0.75 | LMNA (0.66) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| Hydrochloric Acid SCHEMBL30150738 | 0.74 | HTT (0.65) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA | |
| SCHEMBL28996851 | 0.73 | CYP1A2 (0.55) | CYP1A2HIF1ASMN1; SMN2CDK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-20240277872-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-20240229109-A1 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | MODERNATX, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4314332-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2022241045-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2026103877-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4737574-A2 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4573215-B1 | CELL-FREE METHOD OF PRODUCING SYNTHETIC CIRCULAR NUCLEIC ACID | ALDEVRON L L C (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277872-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | NSUN3, NSUN2, RNGTT | CYP1A2 4586/4885HIF1A 2629/4885SMN1; SMN2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.